The prognostic signature based on glycolysis-immune related genes for acute myeloid leukemia patients.

• Glycolytic genes combined with immune score could define differential prognoses of AML patients. • The Risk Score calculated by LASSO Cox model based on 6 genes (METTL7B, HTR7, ITGAX, TNNI2, SIX3 and PURG) can reliably predict the prognosis of AML patients. • Nomogram model based on Risk Score and other independent prognostic factors could also predict the prognosis and survival of AML patients. Acute myeloid leukemia (AML) is widely considered an immunoresponsive malignancy. However, potential association between glycolysis-immune related genes and AML patients' prognosis has been seldom studied. AML-related data was downloaded from TCGA and GEO databases. We grouped patients according to Glycolysis status, Immune Score and combination analysis, basing on which overlapped differentially expressed genes (DEGs) were identified. The Risk Score model was then established. The results showed that totally 142 overlapped genes were probably correlated with glycolysis-immunity in AML patients, among which 6 optimal genes were screened to construct Risk Score. High Risk Score was an independent poor prognostic factor for AML. In conclusion, we established a relatively reliable prognostic signature of AML based on glycolysis-immunity related genes, including METTL7B, HTR7, ITGAX, TNNI2, SIX3 and PURG. [ABSTRACT FROM AUTHOR]